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Abstract 
Central endothelin (ET) has been implicated in the regulation of the cardiovascular system. The effect of intracerebroventric- 
ular (i.c.v.) administration of ET-1 or IRL 1620 (5, 15 and 45 ng) on the systemic hemodynamics and regional circulation was 
studied in anesthetized rats using a radioactive microsphere t chnique. Systemic hemodynamics and regional blood circulation 
were determined before (baseline) and at 30 min after the injection of each dose of ET-1 or IRL 1620. Administration of saline 
(5/xl, i.c.v.) did not produce any significant cardiovascular effects. The lower doses of ET-1 (5 and 15 ng) did not produce any 
significant effect on blood pressure (BP), heart rate (HR), cardiac output (CO), stroke volume (SV), total peripheral resistance 
(TPR) and regional blood circulation. However, the higher dose (45 ng) produced a transient rise (26%) followed by a sustained 
fall (48%) in BP. The decrease in BP was accompanied by significant decreases in CO (44%) and SV (39%), while HR and TPR 
were not affected. ET-1 (45 ng, i.c.v.) also produced a significant reduction in blood flow to the brain (75%), heart (49%), kidneys 
(66%), GIT (40%), portal system (52%) and muscuio-skeletal system (38%), while blood flow to the skin was not affected. To 
determine pharmacological specificity of the central effects of ET-1, studies were performed in rats pretreated with BQ-123, a 
specific ET A receptor antagonist. Pretreatment with BQ-123 (10 /zg, i.c.v.), 15 min prior to the administration of ET-1, 
completely antagonized the systemic hemodynamic aswell as the regional circulatory effects of ET-1 (45 ng, i.c.v.). In order to 
determine whether stimulation of central ET B receptors produces any cardiovascular effects, studies were performed using IRL 
1620, a specific ET B receptor agonist. Administration of IRL 1620 (5, 15 and 45 ng, i.c.v) did not produce any effect on systemic 
hemodynamics and regional blood circulation in rats. It is concluded that ET A but not ET B receptors are involved in the central 
cardiovascular ctions of ET. 
Keywords: Endothelin-1; BQ-123, Cyclo (-D-Trp-D-Asp-Pro-D-Val-Leu-); Regional vascular resistance; IRL 1620, N-Suc- 
(GIu9,Ala11'lS)ET-l(8-21); Regional blood flow; Systemic hemodynamics; Sprague-Dawley rat; Central nervous ystem 
1. Introduction 
Endothelin (ET) is a 21l amino acid peptide origi- 
nally isolated from the culture medium of porcine 
aortic endothelial ceils [45], and characterized as a 
potent vasoconstrictor. There are three distinct iso- 
forms of this peptide, that is, ET-1, ET-2 and ET-3 
[15]. It was identified that ET is also produced by the 
non-endothelial cells, such as neurons and astroglial 
cells [25,26], and that ET-like immunoreactivity was 
present in the paraventricular nucleus, supraoptic nu- 
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cleus [37], hippocampus and cerebellum [17] of porcine 
and rat brain. In human brain, the distribution of ET 
immunoreactive neurons was similar to that of ET 
mRNA [23]. The presence of ET receptors in the CNS 
has been demonstrated by binding and in situ hy- 
bridization studies [8,16,26]. At least two subtypes of 
ET receptors have been identified and cloned; ET A 
and ET B. The affinity rank order for ET A is ET- I  = 
ET-2 > ET-3 [1], and that for ET B is ET-1 = ET-2 = 
ET-3 [33]. Studies have revealed that N-Suc -  
(Glu9,AIa11,15)ET-l(8-21) ( IRL 1620) [40] is a specific 
agonist of ET B receptors, whereas, cyclo (-o-Trp-D- 
Asp-Pro-D-Val-Leu-) (BQ-123) [14] is a specific antago- 
nist of the ET A receptors. 
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Several ines of evidence support he view that cen- 
tral ET plays an important role in cardiovascular regu- 
lation. In urethane-anesthetized an ventilated rats, 
intracisternal dministration f ET-1 (0.1, 1 or 10 pmol) 
resulted in complex cardiovascular changes. There was 
an immediate increase followed by a decrease in blood 
pressure, heart rate and renal sympathetic nerve activ- 
ity, after which all the variables returned to, or often 
exceeded the baseline values [21]. Intracerebroventric- 
ular (i.c.v.) administration f ET-1 (10 and 100 pmol) 
or ET-3 (100 pmol) inhibited the supraspinal micturi- 
tion reflex and this was accompanied by an increase in 
blood pressure in urethane-anesthetized rats [22]. Cen- 
tral ET also has several neuroendocrine actions. It 
stimulates the release of vasopressin [44], catechol- 
amines [27], adrenocorticotropin hormone [27], atrial 
natriuretic factor [44] and oxytocin [34]. It appears that 
the central effects of ET-1 are mediated through acti- 
vation of the sympathetic nervous ystem and release 
of arginine vasopressin because the pressor esponse of 
intracerebroventricular ET-1 was attenuated by gan- 
glion blockers [18,28] and arginine vasopressin receptor 
antagonist [18]. ET-1 also produces evere vasocon- 
striction of the cerebral arteries [4,32]. Topical applica- 
tion of ET-1 to the middle cerebral artery results in 
ischemia which is distal to and in the cortical territory 
of the middle cerebral artery [31]. 
The role of central ET mechanisms in the develop- 
ment of hypertension has been studied in several labo- 
ratories. It was found that ET receptors are present in 
high densities in the cardiovascular regulatory areas of 
the brain [2,12]. ET receptors were found to be down- 
regulated in the hypothalamus and ventrolateral 
medulla of spontaneously h pertensive rats [11], impli- 
cating the role of central ET in cardiovascular regula- 
tion. Although studies have been performed to deter- 
mine the effect of centrally administered ET on blood 
pressure and heart rate, no study has been performed 
to determine the effect of centrally administered ET 
on the regional blood circulation and to determine the 
subtype of ET receptors involved in cardiovascular 
regulation. In the present study, we have investigated 
the effect centrally administered ET-1 and IRL 1620 
on systemic hemodynamics and regional blood circula- 
tion of anesthetized rats. 
2. Material and methods 
2.1. Animals and surgical preparations 
Male Sprague-Dawley rats (Sasco-King Animal Co., 
Oregon, WI) weighing 350-400 g were used in the 
study. Rats were anesthetized with sodium pentobarbi- 
tone (50 mg/kg, i.p.) and the lateral cerebral ventricle 
was cannulated by placing the rat in a stereotaxic 
device (David Kopf Instruments, CA) and fixing the 
cannula (using the coordinates: 4.5 mm lateral, 4 mm 
caudal to bregma nd 6 mm deep from the bone) with 
dental cement. The animals were allowed to recover 
from surgery for at least 7 days before the experiments 
were commenced. The volume of drug injection was 5 
/~1. After each experiment, methylene blue dye was 
injected and the placement of cannula was confirmed 
by observing the site and extent of staining. 
The rats were anesthetized with urethane (1.5 g/kg, 
i.p.) and the left femoral vein was cannulated (PE 50 
tubing, Clay Adams, Parsipanny, N J) for drug adminis- 
tration. The left femoral artery was cannulated (PE 50 
tubing) and connected to a Gould P23 ID pressure 
transducer (Grass Instruments, Quincy, MA) for 
recording the blood pressure on a P7D polygraph 
(Grass Instruments, Quincy, MA) through a 7PI 
preamplifier. The heart rate was recorded through a 
7P4B Grass tachograph, triggered from blood pressure 
signals. In order to keep the blood pO2, pCO 2 and pH 
constant, and to avoid the effect of respiration on 
cardiovascular parameters, animals were kept on con- 
stant rate artificial respiration by inserting an endotra- 
cheal cannula connected to a rodent ventilator (Model 
683, Harvard Apparatus, South Natick, MA). The 
carotid artery of the right side was exposed and a PE 
50 cannula was guided through the common carotid 
artery into the left ventricle. The presence of the 
cannula in the left ventricle was confirmed by record- 
ing the pressure on a polygraph using a pressure trans- 
ducer (Statham P23 DC, Grass Instruments, Quincy, 
MA). When the cannula reached the ventricle, dias- 
tolic pressure dropped to zero. The femoral artery of 
the right side was cannulated and connected to a 
withdrawal pump (Model 22, Harvard Apparatus, South 
Natick, MA). A period of 1 h was allowed for stabiliza- 
tion before the injection of drugs. 
2.2. Determination of systemic hemodynamics and re- 
gional blood circulation 
At each measurement, a thoroughly mixed suspen- 
sion of approximately 100,000 microspheres (15 + 1 
/zm diameter) labeled with 465c (Scandium), n3Sn (Tin), 
141Ce (Cerium), 95Nb (Niobium) or X°3Ru (Ruthenium) 
(New England Nuclear Corporation, Boston, MA) in 
0.2 ml saline were injected into the left ventricle and 
flushed with 0.4 ml saline over a 15-s period. In order 
to calculate the blood flow, arterial blood was with- 
drawn at a rate of 0.5 ml/min through the right 
femoral artery. Blood was withdrawn for 90 s starting 
about 5-10 s before the microsphere injection. At the 
end of the experiment, the animals were sacrificed with 
an overdose of sodium pentobarbitone and the tissues 
and organs were dissected out, weighed and placed in 
vials. The following tissues were studied: lungs, heart, 
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liver, stomach, small intestine, cecum, large intestine, 
mesentery and pancreas, spleen, left kidney, right kid- 
ney, left cerebral hemisphere, right cerebral hemi- 
sphere, midbrain, cerebellum, brain stem, skin and the 
rest of the body consisting of muscles and bones. The 
radioactivity in the standards, the blood samples and 
the tissue samples was counted in a Packard Minaxi 
Auto -Gamma 5000 series gamma counter with preset 
windows discriminating the isotope energies. The fol- 
lowing parameters were calculated: (1) cardiac output, 
(2) stroke volume, (3) total peripheral resistance, (4) 
regional blood flow and (5) regional vascular resis- 
tance. The data were calculated using the programs 
described by Saxena et al. [35]. ET-1 or IRL  1620 was 
administered i.c.v, in cumulative doses of 5, 15 and 45 
ng, and its effect on systemic hemodynamics and re- 
gional circulation was studied at 30 min after the 
injection of each dose in normal rats. The effect of 
ET-1 (5, 15 and 45 ng, i.c.v.) was also studied in 
BQ-123 (10 /zg, i.c.v.) treated rats. Pretreatment with 
BQ-123 was done 15 min prior to the administrat ion of 
ET-1. Administrat ion of saline (5/~1, i.c.v.) served as a 
control for all these experiments. The dose of BQ-123 
was selected on the basis of studies conducted by 
Clozel and Watanabe [3] and in our laboratory where 
central administrat ion of BQ-123 (6 to 10 /xg, i.c.v.) 
significantly attenuated the cardiovascular effects of 
centrally administered ET-1. 
2.3. Drugs 
ET-1 (human, porcine) was purchased from Sigma 
Chemicals Company, St. Louis, MO. BQ-123 and IRL 
1620 were purchased from American Peptide Co. Inc., 
Sunnyvale, CA. 
2.4. Statistics 
All data are presented as the mean values + 1 
S.E.M.. Mean blood pressure (BP; mmHg) was calcu- 
lated using the formula [(Systolic BP-Diastolic BP) /3]  
+ Diastolic BP. Heart rate was recorded as beats /min .  
The number  of animals used in saline group, ET-1 
group, ET-1 + BQ-123 group and IRL  1620 group were 
6, 8, 7 and 7, respectively. The data were subjected to 
an analysis of variance followed by a Duncan's  test. A 
level of P < 0.05 was considered significant. 
3. Results 
3.1. Effect of saline, ET-1, ET-1 + BQ-123 or IRL 1620 
on systemic hemodynamics 
Administrat ion of saline in the lateral cerebral ven- 
tricle had no effect on the systemic hemodynamic 
parameters (Table 1). Lower doses of ET-1 (5 and 15 
Table 1 
Effect of ET agonists (5, 15 and 45 ng, i.c.v.) on the systemic hemodynamics of rats 
Parameter Baseline 5 ng 15 ng 45 ng 
Heart rate (beats / min) 
Control (n = 6) 405 + 7 413 _+ 8 414 ± 6 399 ± 10 
ET-1 (n = 8) 373 ± 9 378 ± 7 398 ± 13 345 ± 17 
ET-1 + BQ-123 (n = 7) 360 ± 18 368 ± 23 360 ± 24 351 + 32 
IRL 1620 (n = 7) 390 ± 20 398 ± 20 395 ± 19 387 ± 19 
Blood pressure (mmHg) 
Control (n = 6) 99 ± 6 96 ± 8 97 ± 7 95 ± 6 
ET-I(n=8) 86±5 87±6 89±7 45±3a 
ET-1 + BQ-123 (n = 7) 86 + 3 77 + 4 79 ± 5 84 ± 11 b 
IRL 1620(n = 7) 85 ± 6 75 ± 7 74± 8 71 ± 8 
Cardiac output (ml / min) 
Control (n = 6) 109 ± 11 102 ± 9 102 ± 8 99 ± 9 
ET-I(n=8) 87S7 81S6 79±7 49s6a  
ET-1 + BQ-123 (n = 7) 99 ± 5 103 ± 10 97 ± 18 107 ± 14 b 
IRL 1620 (n = 7) 126 ± 10 120 _+ 10 117 + 13 98 S 11 
Stroke volume (ml) 
Control (n = 6) 0.27 ± 0.03 0.25 :t: 0.02 0.25 ± 0.02 0.25 ± 0.02 
ET-1 (n = 8) 0.23 ± 0.01 0.21 ± 0.01 0.21 ± 0.02 0.14 ± 0.02 a 
ET-1 + BQ-123 (n = 7) 0.27 ± 0.04 0.28 + 0.03 b 0.23 S 0.05 0.28 5:0.03 b 
IRL 1620 (n = 7) 0.32 ± 0.02 0.29 ± 0.01 0.29 ± 0.02 0.27 ± 0.01 
Total peripheral resistance (mmHg / 1 / min) 
Control (n = 6) 986 + 163 1006 ± 153 993 + 119 1026 ± 146 
ET-1 (n = 8) 1036 __. 113 1114 ± 121 1202 + 152 1001 ± 109 
ET-1 + BQ-123 (n = 7) 810 ± 56 833 + 59 880 ± 111 913 + 64 
IRL 1620 (n = 7) 718 ± 51 893 + 53 785 + 75 748 _+ 70 
a Indicates ignificant (P < 0.05) difference as compared to baseline, b Indicates ignificant (P < 0.05) difference as compared to the ET-1 group. 
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ng) produced no significant changes in the systemic 
hemodynamics. The higher dose (45 ng), however, pro- 
duced marked cardiovascular effects. There was an 
initial transient increase followed by a long-lasting de- 
crease in BP after administration of ET-1 (45 ng) (Fig. 
1). ET-1 (45 ng) decreased BP (48%) [F(3,28)= 5.62; 
P = 0.0001], SV (39%) [F(3,28) = 5.15; P = 0.002] and 
CO (44%) [F(3,28) = 6.4; P = 0.001]. The HR and TPR 
were not significantly affected. BQ-123 pretreatment 
completely antagonized the initial increase [F(1,12)= 
5.68; P= 0.03] and subsequent decrease [F(1,12)= 
24.06; P = 0.0004] in BP (Fig. 1). It also antagonized 
the decrease in SV [F(1,13) = 15.8; P = 0.001] and CO 
[F(1,13) = 15.32; P = 0.001] produced by 45 ng of ET-1 
(Table 1). On the other hand, IRL 1620 did not pro- 
duce any effect on the systemic hemodynamic parame- 
ters (Table 1 and Fig. 1). 
3.2. Effect of saline, ET-1, ET-1 + BQ-123 or IRL 1620 
on the brain circulation 
The lower doses of ET-1 (5 and 15 ng) did not 
produce any significant effect on blood flow to the 
brain, whereas, the higher dose (45 ng) produced a 
marked decrease [75%, (F(3,27)= 9.34; P = 0.0005] in 
blood flow 30 min after its injection (Fig. 2). This 
decrease was accompanied by an increase [F(3,27)= 
6.93; P = 0.002] in vascular resistance of the brain. 
Pretreatment with BQ-123 completely antagonized the 
effect of ET-1 (45 ng) on blood flow [F(1,12) = 27.32; 
P = 0.0002] and vascular resistance [F(1,12)= 6.05; P 
= 0.03] of the brain. Administration of IRL 1620 (5, 15 
and 45 ng, i.c.v.) produced no effect on the brain 
circulation (Fig. 2). 
3.3. Effect of saline, ET-1, ET-1 + BQ-123 or IRL 1620 
on the coronary circulation 
Administration of lower doses (5 and 15 ng, i.c.v.) of 
ET-1 produced no effect on coronary blood flow or 
vascular resistance (Fig. 3). The higher dose (45 ng, 
i.c.v.) of ET-1 produced a 49% [F(3,28)= 6.14; P = 
0.004] decrease in coronary blood flow without affect- 
ing vascular esistance (Fig. 3). Pretreatment with BQ- 
123 blocked [F(1,13)= 5.54; P = 0.03] the decrease in 
coronary blood flow induced by 45 ng of ET-1. IRL 
1620 (5, 15 and 45 ng, i.c.v.) had no significant effect on 
the coronary circulation (Fig. 3). 
3.4. Effect of saline, ET-1, ET-1 + BQ-123 or IRL 1620 
on the renal circulation 
The lower doses (5 and 15 ng, i.c.v.) of ET-1 had no 
effect on renal blood flow and vascular esistance (Fig. 
4). However, 45 ng of ET-1 produced a significant 
decrease (66%) [F(3,27)= 14.23; P = 0.0001] in renal 
blood flow. The decrease in blood flow was accompa- 
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Fig. 1. Time course of effect of saline (5/zl, i.c.v., n = 6), ET-1 (5, 15 and 45 ng, i.c.v., n = 8) or IRL 1620 (5, 15 and 45 ng, i.c.v., n = 7) on the 
blood pressure and heart rate. Measurements (mean + S.E.M.) were performed for 30 min after the injection of each dose of ET-1 or IRL 1620. 
ET-1 (5, 15 and 45 ng, i.c.v.) was also administered in BQ-123 pretreated rats (n = 7). BQ-123 (10/~g, i.c.v.) was administered 15 min before the 
injection of ET-1. * Indicates ignificant difference as compared to baseline and # indicates ignificant difference as compared to ET-1 group. 
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nied by an increase (85%) in renal vascular resistance 
[F(3,27) = 4.71; P = 0.0005]. BQ-123 pret reatment  
completely b locked the decrease in renal blood flow 
[F(1,13) = 16.75; P = 0.001] and increase in renal vas- 
cular resistance [F (1 ,12)= 13.85; P= 0.003] induced 
by 45 ng of ET-1. Central ly administered IRL  1620 (5, 
15 and 45 ng, i.c.v.) had no effect on the renal  circula- 
t ion (Fig. 4). 
3.5. Effect of saline, ET-1, ET-1 + BQ-123 or IRL 1620 
on the gastrointestinal tract (GIT) circulation 
The lower doses (5 and 15 ng, i.c.v.) of ET-1 did not 
alter the G IT  circulation, but the higher dose of ET-1 
(45 ng, i.c.v.) reduced blood flow to the G IT  by 40% 
[F(3,28) = 6.59; P = 0.002]! without any change in vas- 
cular resistance (Fig. 5). The decrease in blood flow 
induced by ET-1 was significantly blocked [F (1 ,13)= 
10.3; P = 0.006] by BQ-123 pretreatment .  IRL  1620 (5, 
15 and 45 ng, i.c.v.) did not alter the G IT  circulation. 
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Fig. 2. Effect of saline (5 /~1, i.c.v., n = 6), ET-1 (5, 15 and 45 ng, 
i.c.v., n= 8) or IRL 1620 (5, 15 and 45 ng, i.c.v, n= 7) on the 
cerebral blood flow (ml/min/100 g tissue) and vascular esistance 
(mmHg/ml/min/100 g tissue). Measurements (mean ± S.E.M.) were 
performed before (baseline) and at 30 min after the injection of each 
dose of ET-1 or IRL 1620. ET-1 (5, 15 and 45 ng, i.c.v.) was also 
administered in BQ-123 pretreated rats (n = 7). BQ-123 (10 t~g, 
i.c.v.) was administered 15min before the injection of ET-1. * Indi- 
cates ignificant difference as compared to baseline and # indicates 
significant difference as compared to ET-1 group. 
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Fig. 3. Effect of saline (5 ~1, i.c.v., n = 6), ET-1 (5, 15 and 45 ng, 
i.c.v., n= 8) or IRL 1620 (5, 15 and 45 ng, i.c.v., n = 7) on the 
coronary blood flow (ml/min/100 g tissue) and vascular esistance 
(mmHg/ml/min/100 g tissue). Measurements (mean _+ S.E.M.) were 
performed before (baseline) and at 30 min after the injection of each 
dose of ET-1 or IRL 1620. ET-1 (5, 15 and 45 ng, i.c.v.) was also 
administered in BQ-123 pretreated rats (n = 7). BQ-123 (10 /.~g, 
i.c.v.) was administered 15min before the injection of ET-1. * Indi- 
cates ignificant difference as compared to baseline and # indicates 
significant difference as compared to ET-1 group. 
3.6. Effect of saline, ET-1, ET-1 + BQ-123 or IRL 1620 
on the portal circulation 
ET-1 (5 and 15 ng, i.c.v.) did not produce any 
change in portal  circulation. High dose (45 ng, i.c.v.) of 
ET-1 decreased the portal  b lood flow by 52% [F(3,26) 
---16.32; P < 0.0001] without affecting vascular resis- 
tance (Fig. 6). This decrease in blood flow was com- 
pletely blocked [F (1 ,13)= 21.67; P = 0.0005] by pre- 
t reatment  with BQ-123. IRL  1620 (5, 15 and 45 ng, 
i.c.v.) administrat ion did not affect the portal  circula- 
tion. 
3. 7. Effect of saline, ET-1, ET-1 + BQ-123 or IRI 1620 
on the musculo-skeletal circulation 
Administ rat ion of ET-1 (5, 15 and 45 ng, i.c.v.) 
produced a dose-re lated ecrease in b lood flow to the 
musculo-skeletal  system (Fig. 7). However,  this de- 
crease was statistically significant [F(3,28) = 2.46; P = 
0.02] only with 45 ng of ET-1. There was no significant 
change observed in vascular esistance. BQ-123 blocked 
[F(1,13) = 6.05; P = 0.02] the decrease in b lood flow 
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produced by 45 ng of ET-1. IRL 1620 (5, 15 and 45 ng, 
i.c.v.) did not produce any significant effect on the 
musculo-skeletal blood flow (Fig. 7). 
3.8. Effect of saline, ET-1, ET-1 + BQ-123 or IRL 1620 
on the skin circulation 
ET-1 (5, 15 or 45 ng, i.c.v.) had no effect on blood 
flow (Fig. 8) to the skin. The 5 ng and 15 ng doses of 
ET-1 had no effect on vascular esistance of the skin, 
but the 45 ng dose of ET-1 produced a significant 
decrease [F(3,20)= 6.1; P= 0.007] in vascular resis- 
tance. In BQ-123 pretreated rats, the skin blood flow 
was significantly increased by 5 ng [F(1,12)= 11.07; 
P = 0.006], 15 ng [F(1,12)= 8.71; P = 0.01] and 45 ng 
[F(1,12) = 7.84; P = 0.01] as compared to ET-1 treated 
animals. The decrease in vascular resistance of skin 
produced by ET-1 (45 ng) was blocked [F(1,11) = 6.89; 
P = 0.02] by BQ-123 pretreatment. IRL 1620 (5, 15 and 
45 ng, i.c.v.) administration produced no change in the 
skin blood circulation (Fig. 8). 
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Fig. 4. Effect of saline (5 pA, i.c.v., n = 6), ET-1 (5, 15 and 45 ng, 
i.c.v., n = 8) or IRL 1620 (5, 15 and 45 ng, i.c.v., n = 7) on the renal 
blood flow (ml /min /100  g tissue) and vascular resistance 
(mmHg/ml /min /100  g tissue). Measurements (mean_+ S.E.M.) were 
performed before (baseline) and at 30 min after the injection of each 
dose of ET-1 or IRL 1620. ET-1 (5, 15 and 45 ng, i.c.v.) was also 
administered in BQ-123 pretreated rats (n = 7). BQ-123 (10 /zg, 
i.c.v.) was administered 15 min before the injection of ET-1. * Indi- 
cates significant difference as compared to baseline and # indicates 
significant difference as compared to ET-1 group. 
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Fig. 5. Effect of saline (5 /zl, i.c.v., n = 6), ET-1 (5, 15 and 45 ng, 
i.c.v., n = 8) or IRL 1620 (5, 15 and 45 ng, i.c.v., n = 7) on the 
gastrointestinal blood flow (ml /min /100  g tissue) and vascular esis- 
tance (mmHg/ml /min /100  g tissue). Measurements (mean _+ S.E.M.) 
were performed before (baseline) and at 30 rain after the injection of 
each dose of ET-1 or IRL 1620. ETA (5, 15 and 45 ng, i.c.v.) was also 
administered in BQ-123 pretreated rats (n = 7). BQ-123 (10 /zg, 
i.c.v.) was administered 15 rnin before the injection of ET-1. * Indi- 
cates significant difference as compared to baseline and # indicates 
significant difference as compared to ET-1 group. 
4. Discussion 
In the present study we have examined the effect of 
intracerebroventricular administration of ET agonists 
on systemic hemodynamics and regional blood circula- 
tion. The lower doses (5 and 15 ng) of centrally admin- 
istered ET were without any effect but the high dose 
(45 ng) of ET-1 caused a biphasic change in blood 
pressure; increase followed by a decrease. Siren et al. 
[38] also found that lower doses of ET-1 (1, 3 and 10 
pmol/kg, i.c.v.) did not produce any effect on blood 
pressure, heart rate, cardiac index and total peripheral 
resistance. However, higher dose of ET-1 (30 pmol/kg, 
i.c.v.) produced a transient increase followed by a 
decrease in blood pressure. These effects were similar 
to those observed in the present study using 45 ng (or 
18 pmol) of ET-1. The biphasic response observed in 
our study confirms ome of the earlier findings. Fergu- 
son et al. [6] observed that injection of ET-1 (2 pmol) 
in the area postrema of anesthetized rats produced a 
significant increase followed by a decrease in blood 
pressure. Hashim et al. [13] also observed that injection 
of ET-1 (30 pmol) in the fourth cerebral ventricle of 
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Fig. 6. Effect of saline (5 /zl, i.c.v., n = 6), ET-1 (5, 15 and 45 ng, 
i.c.v., n ~ 8) or IRL 1620 (5, 15 and 45 ng, i.c.v., n = 7) on the portal 
blood flow (ml /min /100  g tissue) and vascular resistance 
(mmHg/ml /min /100  g tissue). Measurements (mean + S.E.M.) were 
performed before (baseline) and at 30 min after the injection of each 
dose of ET-1 or IRL 1620. ET-1 (5, 15 and 45 ng, i.c.v.) was also 
administered in BQ-123 pretrealced rats (n = 7). BQ-123 (10 ~g, 
i.c.v.) was administered 15 min before the injection of ET-1. * Indi- 
cates significant difference as compared to baseline and # indicates 
significant difference as compared to ET-1 group. 
anesthetized rats produced abiphasic response in blood 
pressure. The observation that central ET-1 induced 
increase in pressor response was suppressed by pre- 
treatment with phenoxybenzamine [30], implicates the 
participation of sympathetic system in the initial pres- 
sor response. Kuwaki et al. [19] reported that the 
intracisternal (i.c.) administration of the lower doses of 
ET-1 elicits a pressor response with increase in renal 
sympathetic nerve activity. However, the higher dose of 
ET-1 (1 or 10 pmol, i.c.) produced a subsequent de- 
pressor response with sympathoinhibition. Similar re- 
sponses were observed when ET-1 was applied directly 
to the ventral surface of medulla. The cardiovascular 
effects of intracisternally administered ET-1 were not 
altered following precollicular decerebration or vago- 
tomy [21]. These studies clearly indicate that central 
ET-1 produces cardiovascular effects mainly through 
the sympathetic nervous system. In addition to the 
sympathetic involvement there is a possibility that ET-1 
may have modulated the release of other neurotrans- 
mitters/modulators. It is known that ET-1 inhibits 
nerve stimulation-evoked release of [3H]norepineph- 
rine [41] and [3H]acetylcholine [42], whereas it stimu- 
lates the release of dopamine [7], substance P [46], 
[3H]o-aspartate [24] and vasopressin [36] in several 
brain structures. The ability of centrally administered 
ET-1 at picomolar doses to affect the cardiovascular 
system further shows the importance of central ET as a 
neuromodulator. 
The cardiovascular effects of centrally administered 
ET-1 are mediated through ET A receptors in the CNS 
because BQ-123, a specific antagonist of ET A recep- 
tors, completely blocked its cardiovascular effects. In 
order to explore whether stimulation of ET a receptors 
in the CNS produces cardiovascular effects, we admin- 
istered IRL 1620, a specific ET B agonist, in the lateral 
cerebral ventricle of rats. It was found that IRL 1620 
did not produce any effect on the cardiovascular sys- 
tem, indicating that ET B receptors in the CNS are not 
involved in the cardiovascular effects of centrally ad- 
ministered ET-1. Earlier studies [19,20] have demon- 
strated that both ET-1 and ET-3 produce biphasic 
responses in BP and HR upon intracisternal injection 
in anesthetized rats but the dose required for ET-1 was 
1 or 10 pmol and that for ET-3 was 100 pmol. At a 100 
times higher dose, ET-3 is also likely to produce some 
actions on ET A receptors. These findings further sup- 
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Fig. 7. Effect of saline (5 /~1, i.c.v., n ffi 6), ET-1 (5, 15 and 45 ng, 
i.c.v., n=8)  or IRL 1620 (5, 15 and 45 ng, i.c.v., n= 7) on the 
musculo-skeletal b ood flow (ml /min /100  g tissue) and vascular 
resistance (mmHg/ml /min /100  g tissue). Measurements (mean+ 
S.E.M.) were performed before (baseline) and at 30 min after the 
injection of each dose of ET-1 or IRL 1620. ET-1 (5, 15 and 45 ng, 
i.c.v.) was also administered in BQ-123 pretreated rats (n = 7). BQ- 
123 (10 ~g, i.c.v.) was administered 15 min before the injection of 
ET-1. * Indicates ignificant difference as compared to baseline and 
# indicates ignificant difference as compared to ET-1 group. 
148 S. Rebello et al. / Brain Research 676 (1995) 141-150 
m BASELINE ~ Sng ~ lSng  ~ 45rig 
20 
O 
~ 10 
0 
SAL INE  ET-1 ET - l+BQ123 IRL1620 
o 
SAL INE  ET-1 ET -1+EQ123 IRL1620 
Fig. 8. Effect of saline (5 ~1, i.c.v., n = 6), ET-1 (5, 15 and 45 ng, 
i.c.v., n = 8) or IRL 1620 (5, 15 and 45 ng, i.c.v., n = 7) on the skin 
blood flow (ml /min/100 g tissue) and vascular resistance 
(mmHg/ml /min /100 g tissue). Measurements (mean + S.E.M.) were 
performed before (baseline) and at 30 min after the injection of each 
dose of ET-1 or IRL 1620. ET-1 (5, 15 and 45 ng, i.c.v.) was also 
administered in BQ-123 pretreated rats (n = 7). BQ-123 (10 /~g, 
i.c.v.) was administered 15 min before the injection of ET-1. * Indi- 
cates significant difference as compared to baseline and # indicates 
significant difference as compared to ET-1 group. 
port our results that ET A receptors are involved in the 
cardiovascular effects of centrally administered ET-1. 
The exact site of ET-1 actions in the CNS in producing 
cardiovascular effects can not be ascertained from the 
present studies. Drugs when administered intracere- 
broventricularly predominantly act upon periventricu- 
lar structures like the hypothalamus and ventral sur- 
face of medulla. Previous studies have implicated sub- 
fornical organ, area postrema [6], nucleus tractus soli- 
tarius [13], hypothalamus [12] and ventral surface of 
medulla [11,19] in the cardiovascular ctions of ET-1. 
It appears that central cardiovascular effects of ET-1 
are mediated through ET A receptor activation in areas 
like hypothalamus and ventral surface of medulla. 
ET-1 in higher doses (45 ng, i.c.v.) produced a very 
severe reduction in blood flow to the brain. The reduc- 
tion in cerebral blood flow (CBF) by ET-1 was not 
merely due to the reduction in cardiac output because 
the reduction in CBF (75%) was much more marked 
than the decrease in CO (44%). Therefore, the reduc- 
tion in CBF was also due to, in addition to reduced 
CO, a direct vasoconstrictor action of ET-1 on the 
cerebral blood vessels. This was confirmed by the ob- 
servation that there was an increase in vascular esis- 
tance of the brain blood vessels following central ET-1 
administration. These findings confirm some earlier 
reports describing the vasoconstrictor actions of ET in 
the CNS. For example, intracerebroventricular admin- 
istration of ET-1 reduces blood flow to the periventric- 
ular brain structures and choroid plexus [10]. Topical 
application of ET-1 to the middle cerebral artery re- 
sults in ischemia which is distal to and in the cortical 
territory of the middle cerebral artery [31]. The reduc- 
tion in CBF by central ET-1 may be clinically relevant 
because in vasospastic disorders such as cerebral is- 
chemia and subarachnoid hemorrhage the release of 
ET-1 is augmented [9,43]. It is also known that ET-1 
levels are increased in the plasma of patients with 
ischemic stroke [47] and in the cerebrospinal fluid of 
patients with subarachnoid hemorrhage [39]. The re- 
duction in CBF by central ET-1 is mediated through 
the ET A receptors because BQ-123 antagonized the 
reduction in CBF and increase in vascular resistance 
induced by central administration of ET-1. The inabil- 
ity of IRL 1620 to affect the CBF further indicates that 
the effects observed with ET-1 were not mediated 
through central ET B receptors. Earlier investigations 
showed that the cerebral blood vessels are contracted 
by ET with a rank order potency of ET-1 > ET-2 >> 
ET-3 [5,32]. Studies are also available showing that 
ET A receptor antagonists prevent the occurrence of 
cerebral vasospasm in several models of subarachnoid 
hemorrhage [3,29]. It is therefore clear that ET A but 
not ET B receptors in the CNS are involved in the 
regulation of CBF. 
This is the first report on the effect of central 
administration of ET agonists on the blood circulation 
of peripheral organs. Central ET-1 reduced blood flow 
to the peripheral organs, such as, the heart, portal 
system, gastrointestinal tract and musculo-skeletal sys- 
tem. This may be due to a decrease in cardiac output 
induced by central ET-1 because the percent decreases 
in blood flow to most of these organs was found to 
closely parallel the percent decrease in CO. It is un- 
likely that the decrease in blood flow to the peripheral 
organs by centrally administered ET-1 was due to its 
leakage to the peripheral sites because it has been 
reported that intravenous administration of 30 pmol 
[13], or 100 ng/kg [18] of ET-1 had no significant 
hemodynamic effect. Furthermore, we did not observe 
any increase in vascular resistance of the peripheral 
organs, suggesting that there was no direct vasocon- 
strictor effect on the peripheral blood vessels. Kidneys 
were the only exception because decrease in the renal 
blood flow was accompanied by an increase in the 
renal vascular esistance. Centrally administered ET-1 
is known to increase the peripheral release of vasoac- 
tive substances [27,28,30,44], and/or  to increase the 
renal sympathetic nerve activity [19]. The increase in 
vascular esistance of the kidneys could be due to local 
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release of vasoactive substances or due to an increased 
responsiveness of renal blood vessels to sympathetic 
stimulation. The regional circulatory effects of cen- 
trally administered of ET-1 appear to be mediated via 
central ET A receptors ince BQ-123 was able to com- 
pletely antagonize the reduction in blood flow to pe- 
ripheral organs induced by ET-1. ET B receptors are 
not involved in central ET-1 induced decrease in blood 
flow to the peripheral organs because central adminis- 
tration of ET B agonist, IRL  1620, did not affect blood 
flow to the peripheral organs. 
In conclusion, observatiions presented here indicate 
that centrally administered ET-1 produces a transient 
increase followed by a long-lasting decrease in blood 
pressure. The depressor effect is due to a reduction in 
stroke volume and cardiac output, which contributes to 
decrease in blood flow to peripheral organs. The cere- 
bral blood flow is further reduced due to a direct 
action of central ET-1 on cerebral blood vessels. The 
cardiovascular effects of ,centrally administered ET-1 
are mediated through ET A but not ET B in the CNS. 
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